CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
NANORESISTANCE focuses on enhancing cancer treatment by targeting the Epidermal Growth Factor Receptor without relying on its external recognition. It employs advanced nanobiotechnology for drug delivery and monitoring, aiming to overcome resistance to therapies and improve treatment outcomes.
NANORESISTANCE introduces for the first time (i) receptor -independent targeting of Epidermal Growth Factor Receptor-kinase activity, (ii) nuclear delivery of anti-Epidermal Growth Factor Receptor therapy with novel grafting techniques and (iii) the deciphering of resistance and lack of responsiveness to anti-EGFR therapies in the preclinical setting with mathematical models of interstitial biodistribution.
This work defines an unprecedented integrated approach for the comprehensive management…
E.P.O.S. IASIS RESEARCH AND DEVELOPMENT LTD
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
United Kingdom, LONDON
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
LONDON
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
DEMOCRITUS UNIVERSITY OF THRACE (DUTH)
Greece, KOMOTINI
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
France, PARIS
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
